Mangoceuticals

MGRX

Capitalización de mercado USD 6.44 M

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company's Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Mangoceuticals, Inc. (NASDAQ: MGRX) and Nuclea Energy Inc. Halper Sadeh encourages Mangoceuticals shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Mangoceuticals and its board of directors violated the federa.

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter capacity Dallas, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that its merger partner, Nuclea Energy Inc. (“Nuclea”), an advanced nuclear technology company headquartered in Mississauga, Ontario, has signed a non-binding memorandum of understanding (the “MOU”) with New Mining Co. (“New Mining”), a Miami-headquartered provider of high-density digital infrastructure and computing hosting services, to evaluate the technical and structural feasibility of deploying Nuclea's modular reactor technology to serve New Mining's behind-the-meter power needs. “High-density computing infrastructure is precisely the kind of behind-the-meter application our technology is engineered for, and this collaboration enables us to evaluate that fit rigorously alongside a partner who understands large-scale, mission-critical power demand.

The MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter capacity Mississauga, Ontario--(Newsfile Corp. - August 6, 2026) - Nuclea Energy Inc. ("Nuclea"), an advanced nuclear technology company headquartered in Mississauga, Ontario, today announced that it has signed a non-binding memorandum of understanding (the "MOU") with New Mining Co. ("New Mining"), a Miami-headquartered provider of high-density digital infrastructure and computing hosting services, to evaluate the technical and structural feasibility of deploying Nuclea's modular reactor technology to serve New Mining's behind-the-meter power needs. "High-density computing infrastructure is precisely the kind of behind-the-meter application our technology is engineered for, and this collaboration enables us to evaluate that fit rigorously alongside a partner who understands large-scale, mission-critical power demand.

The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab and engagement with the U.S. Department of Energy and Nuclear Regulatory Commission to advance the Morpheus microreactor toward demonstration and deployment Dallas, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that its merger partner's wholly owned subsidiary, Nuclea Energy USA Inc. (“Nuclea USA”), has signed a memorandum of understanding (the “MOU”) with the State of Utah Office of Energy Development (“OED”) to explore the siting of a nuclear test reactor at the Utah San Rafael Energy Lab (“USREL”) to advance the deployment of the Morpheus microreactor. The MOU marks an important step in advancing research, development and commercial deployment of Nuclea's micro-modular reactor.

The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab to advance the Morpheus microreactor toward demonstration and deployment Salt Lake City, Utah--(Newsfile Corp. - August 5, 2026) - Nuclea Energy USA Inc. ("Nuclea USA"), a wholly owned subsidiary of Nuclea Energy Inc. ("Nuclea"), an advanced nuclear technology developer, is pleased to publicly announce the signing of a memorandum of understanding (MOU) on June 2, 2026 with the State of Utah Office of Energy Development ("OED") to explore the siting of a nuclear test reactor at the Utah San Rafael Energy Lab ("USREL") to advance the deployment of Nuclea's Morpheus Micro Reactor. The MOU marks an important step in advancing research, development and commercial deployment of Nuclea's micro modular reactor.

Dallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).The Company now has until February 1, 2027 to meet the requirement for its shares of common stock to maintain a closing bid price of at least US $1.00 per share for a minimum of 10 consecutive business days. Nasdaq granted the extension after determining that Mangoceuticals meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, and following Mangoceuticals providing written notice of its intention to cure the deficiency within the extension period, if necessary, through a reverse stock split.